Chinese experts say the SARS-CoV-2 genome is generally stable across the globe and current mutations of the virus will not affect the potency or development of vaccine candidates, reported China Daily.
Yang Sheng, deputy director of the bureau of drug registration at the National Medical Products Administration, said that all four Chinese vaccines currently in Phase III trials -- three inactivated vaccines and one recombinant adenovirus vector vaccine -- are being tested overseas with approval from foreign health authorities.
Zhang Xinmin, head of the China National Center for Biotechnology Development, said "the virus' mutations have no real impact on vaccine development."
This is due to most vaccine candidates using the genetic material for the virus' spike protein to provoke an immune response, and that ingredient is very stable, he explained.
At year's end, China is expected to have the ability to produce around 610 million doses of COVID-19 yearly, and the annual production capability is expected to reach 1 billion doses next year, said Zheng Zhongwei, head of China's COVID-19 vaccine development task force.
To read more NewsPoints articles, click here.